Cardioprotection in Diabetes: A Changing Landscape


Dr Jamshed J Dalal, Mumbai    06 January 2018

  1. Holistic CV risk management in diabetes involves control of multiple CV risk factors with statins/antihypertensives/antiplatelets.
  2. Role of the older antidiabetic agents remains controversial, although metformin provides cardioprotection. Among the newer classes, SGLT-2 inhibitors and GLP-1 agonists have demonstrated benefits in reducing CV events in diabetes.
  3. Newer antidiabetic drugs may be considered as vasculoprotective along with glycemic control.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.